Stockreport

Ziopharm's Pause On Its Phase 3 Brain Cancer Study Is More Valuable Than You Think [Seeking Alpha]

ARMO BIOSCIENCES  (ARMO) 
US:NASDAQ Investor Relations: armobio.com
PDF Ziopharm's Pause On Its Phase 3 Brain Cancer Study Is More Valuable Than You ThinkSummaryZiopharm Oncology announced that the phase 3 trial using Ad-RTS-hIL-12 plus vele [Read more]